Product Name:4-Amino-6-chloro-5-hydroxypyrimidine

IUPAC Name:4-amino-6-chloropyrimidin-5-ol

CAS:38953-42-3
Molecular Formula:C4H4ClN3O
Purity:95%+
Catalog Number:CM116619
Molecular Weight:145.55

Packing Unit Available Stock Price($) Quantity
CM116619-100mg in stock ƻǕ
CM116619-250mg in stock ŭƅ
CM116619-1g in stock ŔƏș
CM116619-5g in stock ƻƏŭ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:38953-42-3
Molecular Formula:C4H4ClN3O
Melting Point:-
Smiles Code:OC1=C(Cl)N=CN=C1N
Density:
Catalog Number:CM116619
Molecular Weight:145.55
Boiling Point:312.5°C at 760 mmHg
MDL No:MFCD13689013
Storage:Store at room temperature

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Remibrutinib
Novartis announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib - a highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor - in people with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. In the studies, remibrutinib met all primary and secondary endpoints at Week 12. Remibrutinib is a potential 'best-in-class' BTK inhibitor. It can covalently bind to the BTK enzyme of B cells and myeloid cells. While strongly inhibiting BTK activity, it reduces the systemic exposure of the drug and reduces the risk of adverse events and drug interactions.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.